Front. Pharmacol.Frontiers in PharmacologyFront. Pharmacol.1663-9812Frontiers Media S.A.164682410.3389/fphar.2025.1646824PharmacologyCorrectionCorrection: Efficacy and safety of oral Chinese medicine combined with chemotherapy: a systematic review and network meta-analysisMa et al.10.3389/fphar.2025.1646824MaYuqiLiJiaLiuLiyun*†ShenTao*†School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China
Approved by:Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Liyun Liu, mayuqi1998@proton.me; Tao Shen, mayuqi19980926@outlook.com
These authors have contributed equally to this work
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Correction on Efficacy and safety of oral Chinese medicine combined with chemotherapy: a systematic review and network meta-analysis by Ma Y, Li J, Liu L and Shen T (2025). Front. Pharmacol. 16:1579613. doi: 10.3389/fphar.2025.1579613non-small-cell lung cancertraditional Chinese medicinenetwork meta-analysisoral Chinese medicinesafetysection-at-acceptanceEthnopharmacology
The figure graphics and captions for Figures 2, 3 were reversed in the published article. Figure 2 was incorrectly linked to the Figure 3 graphic, with the caption ‘Network graphs of outcomes. (A) Objective response rate. (B) TP therapy’, while Figure 3 was incorrectly linked to the Figure 2 graphic, with the caption ‘Risk of Bias Summary’. The in-text citations were correct. The graphic and caption order have now been corrected.
Risk of bias summary.
A risk assessment table evaluates studies from 2003 to 2023 across five categories: randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result. Each category is marked with symbols: green plus (low risk), yellow question mark (some concerns), or red minus (high risk). The overall assessment is indicated by the yellow exclamation mark for most cases, suggesting some concerns.
Two network diagrams labeled A and B. Diagram A shows a central node labeled "Cisplatin" connected to nodes "JFK+Cisplatin," "TFS+Cisplatin," "HS+Cisplatin," "XK+Cisplatin," and "TGT+Cisplatin" with varying line thickness. Diagram B displays a central node labeled "Cisplatin/Paclitaxel" connected to nodes "HS+Cisplatin/Paclitaxel," "FZ+Cisplatin/Paclitaxel," "JFK+Cisplatin/Paclitaxel," and "TGT+Cisplatin/Paclitaxel." Both diagrams use blue nodes and black lines.
The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.